NCT02250157 2022-02-22
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
Athenex, Inc.
Phase 1 Completed
Athenex, Inc.
Children's Hospital Medical Center, Cincinnati
Dana-Farber Cancer Institute
Hanmi Pharmaceutical Company Limited
National University Hospital, Singapore
Dana-Farber Cancer Institute